Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1972 2
1973 1
1974 3
1975 2
1976 6
1977 12
1978 9
1979 26
1980 18
1981 28
1982 30
1983 24
1984 35
1985 32
1986 31
1987 34
1988 33
1989 27
1990 29
1991 20
1992 27
1993 24
1994 37
1995 24
1996 36
1997 24
1998 33
1999 34
2000 27
2001 20
2002 22
2003 22
2004 35
2005 32
2006 22
2007 22
2008 23
2009 28
2010 25
2011 23
2012 27
2013 21
2014 20
2015 20
2016 30
2017 22
2018 17
2019 26
2020 24
2021 16
2022 11
2023 14
2024 17
2025 19
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,182 results

Results by year

Filters applied: . Clear all
Page 1
Glucagonoma syndrome.
Bloom SR, Polak JM. Bloom SR, et al. Am J Med. 1987 May 29;82(5B):25-36. doi: 10.1016/0002-9343(87)90424-4. Am J Med. 1987. PMID: 2884877 Review.
The glucagonoma syndrome is characterized by a necrolytic migratory erythematous rash, angular stomatitis, painful glossitis, a normochromic normocytic anemia, mild diabetes mellitus, weight loss, a tendency to thrombosis, and neuropsychiatric disturbances. ...
The glucagonoma syndrome is characterized by a necrolytic migratory erythematous rash, angular stomatitis, painful glossitis, …
Glucagonoma and Glucagonoma Syndrome: An Updated Review.
Anelli S, Mazzilli R, Zamponi V, Giorgini B, Golisano B, Mancini C, Russo F, Panzuto F, Faggiano A. Anelli S, et al. Clin Endocrinol (Oxf). 2025 Oct;103(4):417-426. doi: 10.1111/cen.15300. Epub 2025 Jul 4. Clin Endocrinol (Oxf). 2025. PMID: 40613421 Free PMC article. Review.
BACKGROUND: Glucagonoma is a rare well-differentiated slowly proliferating pancreatic neuroendocrine tumour, characterized by several manifestations including necrolytic migratory erythema, weight loss, diabetes and anaemia. ...The comparison with previous series highlight …
BACKGROUND: Glucagonoma is a rare well-differentiated slowly proliferating pancreatic neuroendocrine tumour, characterized by several …
Glucagonoma syndrome: a review and update on treatment.
John AM, Schwartz RA. John AM, et al. J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2016-2022. doi: 10.1111/jdv.13752. Epub 2016 Jul 16. J Eur Acad Dermatol Venereol. 2016. PMID: 27422767 Review.
NME is usually a specific and often initial finding of glucagonoma syndrome, but it may occur in other settings unassociated with an alpha-cell pancreatic tumour (pseudoglucagonoma syndrome). Glucagonoma syndrome must be distinguished from pseud …
NME is usually a specific and often initial finding of glucagonoma syndrome, but it may occur in other settings unassociated w …
[Glucagonoma syndrome].
Tellechea O, Baptista AP. Tellechea O, et al. Acta Med Port. 1988 Mar-Apr;1(2):149-52. Acta Med Port. 1988. PMID: 2849866 Free article. Review. Portuguese. No abstract available.
European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.
Hofland J, Falconi M, Christ E, Castaño JP, Faggiano A, Lamarca A, Perren A, Petrucci S, Prasad V, Ruszniewski P, Thirlwell C, Vullierme MP, Welin S, Bartsch DK. Hofland J, et al. J Neuroendocrinol. 2023 Aug;35(8):e13318. doi: 10.1111/jne.13318. Epub 2023 Aug 14. J Neuroendocrinol. 2023. PMID: 37578384 Free article.
This ENETS guidance paper aims to provide practical advice to clinicians for the diagnosis, treatment and follow-up of functioning syndromes in pancreatic neuroendocrine tumours (NET). A NET-associated functioning syndrome is defined by the presence of a clinical syndro …
This ENETS guidance paper aims to provide practical advice to clinicians for the diagnosis, treatment and follow-up of functioning syndromes …
The glucagonoma syndrome.
Wynick D, Hammond PJ, Bloom SR. Wynick D, et al. Clin Dermatol. 1993 Jan-Mar;11(1):93-7. doi: 10.1016/0738-081x(93)90103-j. Clin Dermatol. 1993. PMID: 8339206 Review. No abstract available.
Glucagonoma tumors and syndrome.
Montenegro-Rodas F, Samaan NA. Montenegro-Rodas F, et al. Curr Probl Cancer. 1981 Dec;6(6):1-54. doi: 10.1016/s0147-0272(81)80014-1. Curr Probl Cancer. 1981. PMID: 6276079 Review. No abstract available.
[Glucagonoma syndrome].
Levitskaia ZI, Balabolkin MI, Gordina AA. Levitskaia ZI, et al. Ter Arkh. 1987;59(11):137-42. Ter Arkh. 1987. PMID: 2831631 Review. Russian. No abstract available.
[Glucagonoma syndrome].
Antonov AV. Antonov AV. Probl Endokrinol (Mosk). 1987 Jan-Feb;33(1):70-8. Probl Endokrinol (Mosk). 1987. PMID: 3029750 Review. Russian. No abstract available.
Glucagonoma syndrome.
Adams DR, Miller JJ, Seraphin KE. Adams DR, et al. J Am Acad Dermatol. 2005 Oct;53(4):690-1. doi: 10.1016/j.jaad.2005.04.071. J Am Acad Dermatol. 2005. PMID: 16198793 No abstract available.
1,182 results